CoreMap Raises $37 Million in Series C Funding
CoreMap, a company based in Burlington, Massachusetts, has announced a successful Series C funding round, securing $37 million. The round was led by Medtronic, a prominent player in the medical technology field.
Company Background
CoreMap specializes in developing advanced cardiac mapping technology designed to improve the diagnosis and treatment of atrial fibrillation and other complex arrhythmias. Founded by Sarah Kalil, who serves as both CEO and President, the company is focused on enhancing cardiac care through innovative solutions.
Leadership
Sarah Kalil, Co-Founder and CEO of CoreMap, expressed her enthusiasm for this latest funding milestone. "This investment will allow us to accelerate the development of our cardiac mapping technology and bring it closer to patients who need it," Kalil stated.
Investment Details
The Series C funding round, led by Medtronic, brings significant financial resources to CoreMap. While additional investors were not disclosed, Medtronic's involvement highlights the strategic importance of CoreMap's technology in the medical field.
Planned Use of Funds
The funds from this round are earmarked for further development of CoreMap's cardiac mapping systems. The company plans to enhance its technology to provide even more precise and effective diagnostic tools for cardiologists. This investment will also support the scaling of operations as CoreMap aims to expand its market presence.
Conclusion
With this new influx of capital, CoreMap is well-positioned to continue its mission of advancing cardiac care through innovative technology. As the company moves forward, the support from Medtronic underscores the potential impact of CoreMap's solutions in the healthcare industry.